Biotech Stocks Soar Amid Positive News – Biogen Idec Inc …

Biotech Stocks Soar Amid Positive News – Biogen Idec Inc …

Related

BIIBStifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, OvervaluationBenzinga’s Top #PreMarket LosersIs Biogen Stock Worth Considering Right Now?(Seeking Alpha)

Related

GILDGilead Shares Tumble On Drug Warning; Baird Says BuyBenzinga’s Top #PreMarket LosersSeeking Alpha’s Biotech Weekly: Biogen’s Plaque Attack, Amgen Or Gilead?, And More(Seeking Alpha)

A number of biotech stocks were soaring in Friday’s premarket following positive news.

Biogen Idec Inc (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037) which showed statistical significance with 3mg, 10mg doses for Alzheimer’s treatment.

Biogen Idec traded at $464.71 in the premarket, up 7.16 percent

Gilead Sciences, Inc. (NASDAQ: GILD) moved higher following positive comments from Argus, which expected continued strength for its antiviral and oncology drugs.

Gilead Sciences traded at $102.40, up 0.95 percent.

Prothena Corporation PLC (NASDAQ: PRTA) reported that its PRX002 protein Immunotherapy for Parkinson’s Disease met primary objective of Phase 1 study, found to be safe, well tolerated.

Prothena soared to $41.87 in the premarket, up 43.24 percent.

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported that data showed OCA-treated patients with nonalcoholic steatohepatitis (NASH) saw improvements in its Phase 2b FLINT trial.

Intercept Pharmaceuticals surged 8 percent to $311.71.

Posted-In: Biotech News Movers General

View post:

Biotech Stocks Soar Amid Positive News – Biogen Idec Inc …

Share this post

Comments (0)